Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for PAZOPANIB HYDROCHLORIDE
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
- Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
- Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
- Phase II Study of Chiauranib Capsule in Advanced or Unresectable Soft Tissue Sarcoma
- Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
- Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Young Adults
- HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
- Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype
- Ezetimibe Utilization Early After Acute Myocardial Infarction, "EzAMI Trial"
- Pemetrexed, Cisplatin With Soft Tissue Sarcoma
- A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation
- Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- Pazopanib Effects on Bleeding in Hereditary Hemorrhagic Telangiectasia
- Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
- A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma
- A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
- Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib
- Nanoparticle Albumin-Bound Rapamycin and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
- Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
- A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors
- Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
- NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma
- Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)
- Testosterone in Metastatic Renal Cell Carcinoma Patients
- Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
- Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
- Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment
- Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
- PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
- Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
- Pazopanib Vs. Local Therapy for Renal Cancer With Metastases
- Study With Improved Solubility Pazopanib
- Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
- Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma
- Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors
- Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
- Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
- A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
- REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression
- Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients
- Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy
- Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
- Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
- Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
- Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
- Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma
- Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer
- Pazopanib for Treating Uterine Leiomyosarcoma
- Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma
- Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
- Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
- Phase II Study of Pazopanib and Topotecan in Cervical Cancer
- SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
- Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)
- Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
- Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
- A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
- Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours
- Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
- Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
- Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)
- Evaluation of Votrient in Angiosarcoma
- Pazopanib Maintenance Phase II
- Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
- Pazopanib vs. Pazopanib Plus Gemcitabine
- Pazopanib in Molecularly Selected Patients With Advanced NSCLC
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
- Pazopanib Tolerability When Given With Food
- Second Line Sorafenib After Pazopanib in Patients With RCC
- Pazopanib for Metastatic Alveolar Soft Part Sarcoma
- Optimizing Pazopanib Exposure in RCC Patients
- Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma
- PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
- Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
- SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
- Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer
- Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
- Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS
- Combined Modality Treatment of Sarcomas of the Extremities
- A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
- [18F]Fluciclatide PET Imaging of Pazopanib Response
- Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
- Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
- Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma
- PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
- A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma
- Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
- Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
- A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
- Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
- Pazopanib Maintenance for SCLC
- A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer
- 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
- Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
- Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
- Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors
- Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
- Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer
- Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
- Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
- Pazopanib in Relapsed and Refractory Small Cell Lung Cancer
- Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
- Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
- Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
- Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
- NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
- Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer
- Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria
- Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
- Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
- PF-03446962 in Relapsed or Refractory Urothelial Cancer
- Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
- A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
- A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
- Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
- Pazopanib in Second-line Therapy in Renal Cell Carcinoma
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
- Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
- Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
- Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
- Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
- Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma
- Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
- A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
- pazopanib_NCRCC,Ph2 STUDY
- Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
- Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
- First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
- Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
- Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
- Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
- FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer
- Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer
- Dose Escalation Study of Pazopanib Plus TH-302
- Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
- Pazopanib and ARQ 197 for Advanced Solid Tumors
- Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
- Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
- Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
- Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
- Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
- Hepatic Monitoring for Pazopanib
- Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
- Cardiovascular and Torsades de Pointes Monitoring for Pazopanib
- Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine
- Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
- Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome
- Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
- Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
- Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
- Rotating Pazopanib and Everolimus to Avoid Resistance
- Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
- Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
- Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
- HYPAZ: Hypertension Induced by Pazopanib
- Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
- Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
- Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
- Pazopanib, Docetaxel, Prednisone Prostate
- Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
- Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
- Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
- Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
- Neoadjuvant Pazopanib in Renal Cell Carcinoma
- Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
- Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies
- Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
- Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
- A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
- Pazopanib as Single Agent in Advanced NETs
- Pazopanib and Vinflunine in Urothelial Cancer of the Bladder
- Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
- Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer
- Treatment of Corneal Neovascularization With Topical Pazopanib
- Brivanib Metastatic Renal Cell Carcinoma
- Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
- Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
- Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer
- Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
- A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
- Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women
- Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
- Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
- Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy
- VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK
- Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
- Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
- Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer
- Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors
- Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
- Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
- A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration
- Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
- Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
- A Study of Pazopanib With CAPEOX in AGC Patients
- A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
- Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
- Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
- Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
- Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
- Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors
- A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers
- Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
- Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
- Phase II Pazopanib Study in Advanced Dermatofibrosarcomas
- A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans
- GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
- Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
- Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment
- Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
- Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
- An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
- Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
- Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
- Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer
- Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
- Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery
- VEG111485: A QTc Study of Pazopanib
- Treatment With Pazopanib for Neoadjuvant Breast Cancer
- A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
- Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors
- S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors
- Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
- Adjuvant Pazopanib in Stage I NSCLC
- Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
- An Extension to Study MD7108240
- Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
- Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
- A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
- Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
- A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors
- Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function
- Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops
- Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
- A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
- Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer
- To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
- Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
- Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
- Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
- Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
- Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
- Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
- Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
- Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
- Pazopanib in Treating Patients With Metastatic Urothelial Cancer
- A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.
- Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
- Pazopanib in Treating Patients With Recurrent Glioblastoma
- Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
- Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
- Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer
- Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery
- Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
- A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes
- Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
- Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
- Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)
- Study To Assess Long Term Safety Of Pazopanib
- A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
- Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
- A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
- Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
- Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma
- Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
- Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
- Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
- Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
- GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Clinical trials list
click for details